drugset / Trial / NCT01474863
Citrulline in Severe Sepsis
RandomizedSingle-groupTriple-blindPrevention
Summary
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis is that intravenous L-citrulline will decreased the development or progression of acute lung injury in patients with severe sepsis compared to placebo.
Timeline
- Start
- 2012-08
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | L-citrulline | Other / unclassified | 4.5 mg/kg | Intravenous |
| Comparator | L-citrulline | Other / unclassified | 9 mg/kg | Intravenous |